Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
NEW YORK, Nov. 28, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased shares of ProNAi Therapeutics, Inc. (“ProNAi”) (NASDAQ:DNAI) between July 15, 2015 and June 6, 2016 (the “Class Period”). You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra/pronai-therapeutics-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, ProNAi made materially false and misleading statements about the potential and efficacy of its drug product candidate PNT2258 in the company’s public filings, which caused ProNAi’s stock price to be artificially inflated throughout the Class Period, thus harming investors.
On June 6, 2016, ProNAi revealed that the Phase 2 clinical trials of PNT2258 failed to produce sufficient efficacy results to justify continued clinical development of the drug and, thus, ProNAi was suspending clinical development of PNT2258. Following this news, shares of ProNAi fell more than 67 percent.
If you suffered a loss in ProNAi you have until January 9, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
